Valuation: Caplin Point Laboratories Limited

Market Cap 19TCr 195.22Cr 171.69Cr 159.5Cr 146.7Cr 275.11Cr 280.04Cr 1.91TCr 743.96Cr 9.22TCr 732.89Cr 717.04Cr 32TCr P/E 2026
17.9x
P/E 2027 * 26.5x
Enterprise Value 19TCr 195.22Cr 171.69Cr 159.5Cr 146.7Cr 275.11Cr 280.04Cr 1.91TCr 743.96Cr 9.22TCr 732.89Cr 717.04Cr 32TCr EV / Sales 2026
5.23x
EV / Sales 2027 * 7.6x
Free-Float
26.39%
Yield 2026 *
-
Yield 2027 * 0.16%
1 day+0.61%
1 week-4.27%
Current month-4.64%
1 month-0.63%
3 months+45.76%
6 months+44.75%
Current year+35.91%
1 week 2,455
Extreme 2455
2,680
1 month 2,455
Extreme 2455
2,700
Current year 1,502.45
Extreme 1502.45
2,700
1 year 1,502.45
Extreme 1502.45
2,700
3 years 838.7
Extreme 838.7
2,700
5 years 575
Extreme 575
2,700
10 years 180
Extreme 180
2,700
Manager TitleAgeSince
Chief Executive Officer 71 28/03/2015
Director of Finance/CFO - 19/02/2016
Chief Administrative Officer - -
Director TitleAgeSince
Director/Board Member - 31/01/2026
Chairman 73 27/01/2010
Director/Board Member - 05/11/2025
Change 5-day change 1-year change 3-year change Capi.($)
+0.79%-4.27%+19.09%+193.18% 195.43Cr
+0.05%+1.09%+15.46%+77.54% 4.83TCr
+2.66%+1.77%+61.61%+112.19% 3.53TCr
+3.30%+1.71%-3.02%+37.57% 1.18TCr
-0.03%-2.54%+14.76%+81.59% 1.16TCr
-0.37%-0.19%+36.83%+136.73% 899.08Cr
+1.54%+0.31%+48.67%-5.90% 692.87Cr
-0.77%-3.48%+13.66%+32.01% 672.41Cr
-0.38%-1.76%+2.43%+178.60% 643.36Cr
+1.60%-15.49%-29.66%+8.47% 566.47Cr
Average +0.83%-2.20%+17.98%+85.20% 1.44TCr
Weighted average by Cap. +0.99%-1.00%+25.76%+84.01%

Financials

2026 2027 *
Net sales 2.13TCr 22Cr 19Cr 18Cr 17Cr 31Cr 32Cr 214.68Cr 84Cr 1.04TCr 82Cr 81Cr 3.6TCr 2.49TCr 26Cr 23Cr 21Cr 19Cr 36Cr 37Cr 251.01Cr 98Cr 1.21TCr 96Cr 94Cr 4.21TCr
Net income 616.2Cr 6.36Cr 5.6Cr 5.2Cr 4.78Cr 8.97Cr 9.13Cr 62Cr 24Cr 300.56Cr 24Cr 23Cr 1.04TCr 712.75Cr 7.36Cr 6.47Cr 6.01Cr 5.53Cr 10Cr 11Cr 72Cr 28Cr 347.65Cr 28Cr 27Cr 1.21TCr
Net Debt - -
Logo Caplin Point Laboratories Limited
Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. The Company's operations include research & development and manufacturing of finished formulations, active pharmaceutical ingredients (APIs), clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa and a USFDA/EU-GMP approved injectable facility. In the Regulated Markets, its products include liquid & lyophilized vials, pre-filled syringes, three-pc ophthalmic droppers and pre-mix bags. In the Emerging Markets, its products include tablets, dry syrups - bottles, soft gels, capsules, suppositories, liquid syrups - bottles, liquid injectables in ampoules & vials, lyophilized vials, prefilled syringes (PFS), and emulsion injection in ampoules & vials.
Employees
3,966
Date Price Change Volume
24/26/24 2,506.75 +0.79% 1,548
23/26/23 ₹2,487.15 +0.25% 9,678
22/26/22 ₹2,480.95 -4.84% 9,799
21/26/21 ₹2,607.05 -1.54% 3,049
20/26/20 ₹2,647.75 +1.29% 2,358
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2,487.15INR
Average target price
2,505.00INR
Spread / Average Target
+0.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CAPLIPOINT Stock